Johnson & Johnson’s stock, we believe, is dependent on growth in emerging markets, which has been showing steady progress and is expected to grow between 9-11% from 2012 to 2017. Another factor is the pharmaceutical pipeline of J&J which has the potential of producing blockbuster drugs. Licensing and co-development agreements have produced successful drugs for the company like Xareleto – a blood thinner - with Bayer. R&D productivity is another important factor impacting the stock price. The company’s medical device and diagnostic segment is also an important aspect adding to the stock price movement. Its growth in emerging markets is helping the company increase its revenues.